Bonus Biogroup Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BBIXF research report →
About the company
Bonus BioGroup Ltd. , a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. The company's products under development include BonoFill for the treatment of bone tissue regeneration in maxillofacial and orthopedic indications, and defects in limb and jaw bones which is in Phase II clinical trial, as well as in a preclinical stage for the treatment of bone augmentation in osteoporosis patients.
- CEO
- Shai Meretzki
- IPO
- 2019
- Employees
- 42
- HQ
- Haifa, ON, IL
Price Chart
- Market Cap
- $128.47M
- P/E
- -19.14
- P/S
- 0.00
- P/B
- -42.81
- EV/EBITDA
- -38.03
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 421.61%
- ROIC
- -379.13%
- Revenue
- $0 · 0.00%
- Net Income
- $-24,372,879 · 12.41%
- EPS
- $-0.04 · -53.36%
- Op Income
- $-22,527,744
- FCF YoY
- 31.51%
- 52W High
- $0.15
- 52W Low
- $0.00
- 50D MA
- $0.13
- 200D MA
- $0.09
- Beta
- 0.79
- Avg Volume
- 215
Get TickerSpark's AI analysis on BBIXF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our BBIXF coverage
Recent articles, reports, and earnings notes.
No research on BBIXF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BBIXF report →Similar companies
Peers in the same neighborhood.